Catapres: A Practical Guide For Patients And Clinicians

Basic Catapres Information

• INN (International Nonproprietary Name): Clonidine
• Brand Names Available In United Kingdom: Catapres (tablets), Catapres‑TTS (transdermal patches); other international brands include Kapvay and Nexiclon XR (extended‑release), Duraclon (injection), and regional generics labelled as Clonidina or Clonidin.
• ATC Code: C02AC01
• Forms & Dosages: Tablets 0.1 mg, 0.2 mg and 0.3 mg; extended‑release tablets 0.1 mg and 0.17 mg; transdermal patches 0.1–0.3 mg/24 hr equivalent; injection 100 mcg/mL.
• Manufacturers In United Kingdom: Major manufacturers supplying Catapres and generics include Boehringer Ingelheim, Mylan, Teva and Sandoz; regional generics may be sourced from other suppliers.
• Registration Status In United Kingdom: Catapres and Catapres‑TTS are registered prescription medicines and appear in UK supply lists; extended‑release products for ADHD (Kapvay, Nexiclon XR) are recognised internationally and referenced by UK clinicians where applicable.
• OTC / Rx Classification: Prescription‑only (Rx) in nearly all jurisdictions.

Key Findings From Recent Trials

Major 2022–2025 Studies

What did recent trials actually show about clonidine?

Large randomised controlled trials and pooled analyses between 2022 and 2025 focused on two main uses for clonidine: adjunctive therapy for resistant hypertension and extended‑release formulations for paediatric ADHD.

For resistant hypertension the trials tested clonidine as an add‑on to existing antihypertensive regimens rather than as first‑line monotherapy.

For ADHD the data concentrated on ER formulations such as Kapvay and Nexiclon XR in children aged six years and older, often in combination with stimulants when single‑agent response was incomplete.

Main Outcomes

What benefit can clinicians and patients reasonably expect?

In hypertension trials clonidine added to multisystem regimens produced modest but clinically relevant reductions in ambulatory systolic blood pressure compared with placebo.

Effect sizes were smaller than those typically seen when ACE inhibitors, ARBs or calcium channel blockers are used as first‑line agents, but clonidine provided an effective adjunctive mechanism in resistant cases.

In paediatric ADHD studies ER clonidine produced statistically significant improvements on hyperactivity and impulsivity scales, and helped with bedtime settling when dosed at night.

Clinical practice frequently uses ER clonidine as part of combination therapy for children who have a partial stimulant response or unacceptable stimulant adverse effects.

Safety Observations

What safety themes emerged across the trials?

The safety profile was consistent with longstanding experience for clonidine: sedation and dry mouth were commonly reported and were leading reasons for dose reduction or stopping treatment.

Bradycardia and orthostatic hypotension occurred in a dose‑related manner and required monitoring during titration, especially when combined with other antihypertensives.

Reports of withdrawal‑related rebound hypertension underline the importance of supervised tapering after prolonged use.

Transdermal systems reduced peak–trough variability but caused more local skin reactions in some patients.

Common branded and formulation references used in the studies included Catapres tablets (0.1–0.3 mg), Catapres‑TTS patches and Kapvay ER 0.1 mg.

Clinical Mechanism Of Action

Layman’s Explanation

How does clonidine calm blood pressure and ADHD symptoms in plain language?

Clonidine is a centrally acting medicine that “turns down” the sympathetic nervous system, which lowers blood pressure and can reduce the overactive signalling that contributes to hyperactivity and impulsiveness.

It is available as tablets, patches or an injectable for specialised epidural use, and the effect depends on how it is delivered.

Scientific Breakdown

What does clonidine do at receptor level?

Clonidine is an imidazoline/α2‑adrenergic receptor agonist (ATC C02AC01) that binds presynaptic α2A receptors in the brainstem, particularly in the locus coeruleus, and to imidazoline I1 sites.

This binding reduces norepinephrine release and sympathetic outflow, producing lowered vascular tone and decreased central arousal.

Pharmacokinetics

What are the practical points about absorption and action?

Oral clonidine tablets (0.1–0.3 mg) are absorbed relatively quickly and require divided dosing for blood pressure control, whereas ER formulations smooth plasma concentrations and are suited to nocturnal dosing for ADHD.

Transdermal patches provide steady 24‑hour delivery and reduce peak–trough swings, which helps adherence and steady effect in some patients.

Epidural injection (Duraclon) gives local effects for severe cancer pain under specialist supervision.

Formulation Differences

Which formulation suits which problem?

Tablets allow flexible titration for hypertension and short‑term adjustments for side effects such as drowsiness.

ER tablets (Kapvay, Nexiclon XR) are designed for once‑daily bedtime dosing in children with ADHD and offer smoother overnight concentrations that support sleep and symptom control.

Transdermal Catapres‑TTS patches are useful where pill adherence is a problem or when a daily steady dose is preferred.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

What is clonidine licensed for in the UK?

In the UK clonidine (Catapres tablets and Catapres‑TTS patches) is an established centrally acting antihypertensive listed as a prescription medicine.

Extended‑release clonidine formulations for ADHD, such as Kapvay and Nexiclon XR, are recognised internationally and are referenced by UK clinicians, though local prescribing follows MHRA and NICE guidance.

Notable Off‑Label Trends

When do clinicians use clonidine beyond its licence?

Specialist teams use clonidine off‑label for opioid or alcohol withdrawal management, and anaesthetists may use epidural Duraclon for refractory cancer pain under hospital governance.

Other experimental or local uses include menopausal flushing and migraine prophylaxis in selected patients, balanced against dose‑related sedation.

Typical therapeutic adult dosing for essential hypertension starts at 0.1 mg twice daily and titrates upwards with a typical maximum around 2.4 mg per day in rare cases.

For ADHD, ER dosing commonly begins at 0.1 mg at bedtime and can be titrated up to 0.4 mg per day in children aged six and older.

Dosage Strategy

General Dosing

How should clinicians approach starting clonidine?

Start low and go slow to reduce the risk of sedation and orthostatic hypotension.

For adults with essential hypertension a common initiation is clonidine 0.1 mg twice daily PO with gradual titration according to blood‑pressure response and tolerability.

Clonidine is most often used as a second‑ or third‑line centrally acting drug or as an adjunct in combination regimens rather than first‑line therapy.

Condition‑Specific Dosing

What are typical regimens by problem?

Hypertension

Start at 0.1 mg twice daily, monitor blood pressure and heart rate, and adjust dose progressively.

Consider Catapres‑TTS transdermal patches for patients with adherence problems or those who tolerate steady dosing better.

ADHD (Paediatric ER Formulations)

Kapvay ER dosing for children aged six years and above typically starts at 0.1 mg at bedtime and increases by 0.1 mg weekly as needed up to 0.4 mg/day.

Specialist paediatric review is recommended prior to initiating ER clonidine formulations for ADHD.

Epidural Duraclon

Duraclon injection for severe cancer pain is managed by anaesthesia or palliative care teams and follows specialist protocols rather than community dosing schedules.

Renal And Elderly Considerations

Reduce dose in renal impairment because the elimination half‑life may extend to approximately 41 hours in severe cases.

Start at lower doses in the elderly and monitor closely for bradycardia and orthostatic symptoms.

Safety Protocols

Contraindications

Who should not receive clonidine?

Absolute contraindications include known hypersensitivity to clonidine or any excipients and severe bradyarrhythmias such as second‑ or third‑degree atrioventricular block in patients without a pacemaker.

Exercise caution in patients with recent myocardial infarction, severe coronary insufficiency, significant bradycardia, advanced renal impairment and uncontrolled depression.

Adverse Effects

What side effects are most likely and which are serious?

Common mild effects include dry mouth, drowsiness or fatigue, headache, constipation and dizziness.

Moderate effects include bradycardia and orthostatic hypotension, which are more likely at higher doses or when combined with other antihypertensives.

Rebound hypertension on abrupt cessation is an important clinical risk and requires supervised tapering.

Transdermal patches can cause local skin reactions; monitor application sites and advise rotation of sites.

In overdose settings expect hypotension, marked bradycardia, somnolence and potential respiratory depression — urgent medical attention is required.

Interaction Mapping

Food Interactions

Are there any foods to avoid with clonidine?

There are no major food interactions, and standard oral administration practices apply.

Avoid excessive alcohol because alcohol and other central nervous system depressants can increase sedation and respiratory depression risk when combined with clonidine.

Transdermal patches should be kept in their original foil pouches until use and applied to intact, non‑irritated skin.

Drug Combinations To Avoid

Which drug combinations need extra caution?

Combining clonidine with other antihypertensives — such as beta‑blockers, calcium channel blockers, ACE inhibitors or ARBs — can enhance hypotension and bradycardia, so monitor blood pressure and heart rate when adding or changing therapies.

Concurrent use of benzodiazepines, opioids or sedative antipsychotics increases the risk of sedation and respiratory depression and should be reviewed before initiation.

MAO inhibitors and sudden sympathetic stimulants can produce unpredictable blood‑pressure responses; use caution and specialist advice where needed.

When used for ADHD, clonidine ER is commonly combined with stimulant therapy but requires careful monitoring of sleep, blood pressure and heart rate.

Patient Experience Analysis

Survey Data

What do real patients say about clonidine?

Service evaluations and registry surveys report mixed satisfaction: many patients achieve improved blood‑pressure control or symptomatic ADHD benefit, while sedation and dry mouth commonly drive discontinuation.

Parents of children using ER clonidine often report improved bedtime settling and better sleep, but some describe daytime somnolence that may limit school‑time functioning.

For adults who struggle with pill adherence, once‑daily transdermal patches often improve real‑world adherence and steadier symptom control.

Forum Trends

What topics come up on UK patient forums?

Online communities discuss dosing schedules, experiences of withdrawal symptoms after missed doses or abrupt stoppage, brand differences between Catapres tablets and patches, and availability issues for branded versus generic products.

Supply and access conversations commonly reference pack formats such as 30‑ or 60‑tablet blister cartons and sealed foil pouches for TTS patches, and manufacturers such as Boehringer Ingelheim, Mylan, Teva and Sandoz.

Distribution And Pricing Landscape

UK Supply Chains

How is clonidine supplied in the United Kingdom?

Distribution relies on national wholesalers and standard NHS supply routes, with Catapres and generics moving through community pharmacies and hospital formularies.

Major international manufacturers supply both branded and generic lines, while regional producers supply volume markets and hospital stock.

Price And Reimbursement Trends

What about cost and NHS coverage?

Tablet clonidine generics are typically low cost per dose, but ER formulations and transdermal patches can be more expensive and are sometimes subject to special prescribing arrangements within the NHS.

Reimbursement follows usual NHS prescribing rules, while private prescriptions reflect community pharmacy pricing.

In our online pharmacy, catapres is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

Comparison Table

Which medicines compete with clonidine for the same indications?

Methyldopa is a centrally acting alternative used especially in pregnancy but carries a risk of sedation and potential hepatotoxicity.

Guanfacine is another α2 agonist that has a longer duration and tends to cause less rebound effect, and it is often preferred in paediatric ADHD where daytime sedation is a concern.

For hypertension, ACE inhibitors, ARBs and calcium channel blockers remain superior first‑line options in most adults and are preferred by guidelines.

Pros And Cons

What are the advantages and disadvantages of clonidine?

Pros: multiple formulations (tablet, ER, transdermal, injectable), effective as an add‑on therapy, established safety profile and low cost for generics.

Cons: sedation and dry mouth are common, risk of rebound hypertension on abrupt withdrawal, requirement for renal dose adjustments and generally lower first‑line efficacy than ACE inhibitors, ARBs or calcium channel blockers for initial hypertension treatment.

Regulatory Status

Global Approvals Overview

How long has clonidine been on the market?

Clonidine has a long regulatory history with FDA approval dating back to the 1970s for hypertension and later approvals for ER formulations in ADHD.

EMA and national EU regulators list clonidine preparations and many generics across member states.

UK Regulatory Specifics

What should UK prescribers bear in mind?

Catapres (tablets), Catapres‑TTS patches and multiple generic clonidine products are prescription‑only medicines in the UK, and hospital use of Duraclon injection is specialist and governed by hospital protocols.

Adverse events should be reported via the Yellow Card scheme for pharmacovigilance of rare or severe reactions.

Consolidated FAQ

Practical Clinician Questions

How should clonidine be stopped safely?

Taper clonidine gradually under supervision to prevent rebound hypertension; do not stop abruptly after chronic therapy.

When should a clinician choose a patch versus tablets?

Choose the patch for adherence problems or when steady 24‑hour delivery is preferable; choose tablets or ER for dosing flexibility and rapid dose changes.

How should dosing be adjusted in renal impairment?

Reduce dose and monitor carefully because the elimination half‑life can extend to about 41 hours in severe renal impairment.

Patient FAQs

Will clonidine make me sleepy?

Drowsiness is common, especially early in treatment, and often improves over several weeks as tolerance develops.

Is clonidine safe for children with ADHD?

ER formulations such as Kapvay and Nexiclon XR are licensed in some jurisdictions for children aged six years and older; UK prescribing should follow specialist advice and local guidance.

What should I do if I miss a dose?

Take the missed dose as soon as remembered unless it is close to the next scheduled dose — do not double up to make up a missed dose.

Visual Guide

How To Explain Formulations To Patients

How can a pharmacist show the choices simply to a patient?

Explain tablets (0.1–0.3 mg) as the flexible option with twice‑daily dosing for blood pressure control.

Describe ER tablets (0.1/0.17 mg) as once‑daily bedtime doses that smooth blood levels and help with overnight symptoms in ADHD.

Show the patch (0.1–0.3 mg/24 hr) as a sealed foil pouch product applied to intact skin for steady delivery and ease when tablets are missed.

Explain the injection (Duraclon 100 mcg/mL) as a specialist hospital treatment for severe pain, not for routine community use.

Clinician Reference Visuals

What quick charts are useful for prescribers?

Provide a simple initiation flowchart: baseline BP/HR → start 0.1 mg BID → reassess after titration step → monitor renal function and heart rate → plan taper if stopping.

Include a tapering algorithm to avoid rebound hypertension and a one‑page interaction checklist highlighting CNS depressants and other antihypertensives.

Storage And Transport

Pharmacy Handling

How should pharmacies store clonidine products?

Store oral tablets at controlled room temperature (20–25°C) and protect them from light and moisture.

Keep transdermal patches sealed in their foil pouches until dispensing to preserve potency and integrity.

Handle injectable Duraclon according to parenteral storage and sterility protocols within hospital pharmacy services.

Patient Storage Advice

How should patients keep and use clonidine at home?

Keep tablets in original blister packs and avoid storing them in bathrooms or other damp areas.

Apply patches to intact, non‑irritated skin, rotate sites and discard used patches safely according to instructions.

Do not freeze suspensions or injectable forms and transport patches in their sealed pouches where possible.

Guidelines For Proper Use

Initiation Checklist

What should be checked before starting clonidine?

Confirm the indication and prescriber authority, obtain baseline blood pressure and heart rate, review current medications for interactions, assess renal and hepatic function, and counsel the patient about sedation and dry mouth.

Choose the most appropriate formulation for the patient’s adherence, symptom pattern and comorbidities.

Monitoring And Discontinuation

How frequently should patients be reviewed?

Arrange follow‑up blood pressure and heart‑rate checks after dose changes and monitor for sedation, orthostatic symptoms and mood changes.

If discontinuing treatment, taper gradually under supervision and document the plan clearly in clinical records to prevent rebound hypertensive crises.

Start lower in elderly patients and reduce doses in renal impairment where the half‑life may be substantially prolonged.

Delivery Across United Kingdom

Quick Reference: Safety And Practical Points

What are the takeaways patients should remember?

Do not stop clonidine suddenly; taper under medical supervision to avoid rebound hypertension.

Report persistent dizziness, fainting, or signs of slow heart rate to a clinician promptly.

Avoid heavy alcohol use while taking clonidine because of increased sedation risk.

Closing Notes For Clinicians And Patients

How should this guide change practice or patient expectations?

Clonidine remains a useful adjunct in resistant hypertension and a valued ER option in paediatric ADHD when used with appropriate monitoring.

Choose formulation to match the clinical goal: tablets for flexibility, ER tablets for nightly ADHD dosing, patches for adherence or steady delivery, and injection for specialist analgesic use.

Prescribers should follow local formulary and MHRA guidance, monitor renal function and heart rate, and counsel patients about common adverse effects such as dry mouth and drowsiness.

Wherever clonidine is prescribed, ensure a documented plan for follow‑up and supervised discontinuation to reduce the risk of withdrawal‑related complications.